Promedius

About:

Delaying aging through AI

Top Investors: TIPS Program, MedTech Innovator, Bigbang Angels, Korea Credit Guarantee Fund, CNTTECH

Description:

Founded in 2019, Promedius stands at the forefront of redefining the aging process through innovative solutions for the early detection and management of musculoskeletal and metabolic diseases, including osteoporosis. Driven by our vision to delay aging through AI, we are dedicated to enhancing the quality of life and extending the healthy lifespan of individuals. Our product, PROS® CXR:OSTEO, represents the world’s first screening solution that leverages chest X-ray images to identify patients who may be at risk of osteoporosis.

Total Funding Amount:

$10.6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Songpadong, Seoul-t'ukpyolsi, South Korea

Founded Date:

2019-09-10

Contact Email:

contact(AT)promedius.ai

Founders:

Hyun-Jin Bae, Jong Chul Ye, Joon Beom Seo

Number of Employees:

11-50

Last Funding Date:

2024-05-29

IPO Status:

Private

Industries:

Medical

Artificial Intelligence (AI)

Software